Clinical Trial

Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase 1, multicenter, open label, single agent dose escalation and combination treatment study of RP3 in adult participants with advanced solid tumors, to evaluate the safety and tolerability of RP3 both as a single agent and in combination with anti-PD1 therapy and to determine the recommended Phase 2 dose (RP2D) of RP3.
Protocol Amendment History 1 change
notable Sponsor changed: Replimune Inc. -> Replimune, Inc. 2026-04-19
Trial Details
NCT Number NCT04735978
Lead Sponsor Replimune Inc.
Collaborators: Bristol-Myers Squibb
Conditions Advanced Solid Tumor
Enrollment 123 participants
Start Date 2020-12-29
Primary Completion 2026-11-30 (estimated)
Study Completion 2026-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-27